Roche de­tails Ale­cen­sa da­ta that may shift the drug to post-surgery ALK-pos­i­tive lung can­cer: #ES­MO23

MADRID — Roche on Sat­ur­day tout­ed ad­di­tion­al da­ta from a study show­ing that its drug Ale­cen­sa of­fers “un­prece­dent­ed” dis­ease-free sur­vival in pa­tients with com­plete­ly re­sect­ed ALK …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.